Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fitstry vs FormidableMD

Fitstry
Graded #292

Lower grade

vs+11.700000000000003
FormidableMD
Graded #71

Higher grade

The verdict

FormidableMD takes it — 73.2/100 to 61.5/100.

FormidableMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FormidableMD is a physician-led, cash-pay telehealth practice based in Florida offering GLP-1 weight-loss treatment — semaglutide and tirzepatide in both FDA-approved and compounded forms, plus oral options…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFormidableMD +26
30
56
Dose & formulationFormidableMD +3
75
78
Clinical oversightFormidableMD +7
81
88
Labs & monitoringFormidableMD +10
73
83
FulfillmentFormidableMD +5
67
72
Contract termsFormidableMD +14
47
61
Fitstry · left barFormidableMD · right bar

The numbers

MetricFitstryFormidableMD
WeighScore61.5/10073.2/100
GradeCC
Scorecard rank#292#71
Semaglutide$179/mo (annual plan, plus a separate fee, compounded)$169/mo (1 mg dose, compounded)
Tirzepatide$269/mo (annual plan, compounded)$199/mo (10 mg dose, compounded)
CoverageCoverage not published1 state
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
Fitstry

Graded #292 · C

Strengths

  • Transparent pricing before you commit — compounded semaglutide from $179/mo, tirzepatide from $269/mo, oral GLP-1 from $209/mo (annual plan)
  • Free screening with a one-time $99 program fee that is fully refunded if a clinician can't prescribe ('Approved, or Your $99 Back')
  • Monthly price bundles a lab panel (CMP, A1c, lipids, TSH), unlimited clinician access, bi-weekly care coaching and a 24/7 Care Line
  • Runs under Weightstry, LLC, a LegitScript-certified practice with an independently verifiable seal, a named support email and phone
  • Full compounded lineup — weekly injection, daily oral tablet and microdosing options

Where it loses points

  • Month-to-month pricing is notably higher than the annual plan ($249 vs $179 semaglutide, $339 vs $269 tirzepatide)
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Framed for women 40+, and serves 49 states rather than all 50 (the excluded state isn't disclosed publicly)
  • Works with state-licensed compounding pharmacies but doesn't name a specific pharmacy partner on the Fitstry page
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
FormidableMD

Graded #71 · C

Strengths

  • Transparent, published dose-by-dose pricing for semaglutide ($169-$269/mo) and tirzepatide ($199-$319/mo) with no membership or commitment
  • Offers both FDA-approved and compounded GLP-1s (plus oral options) from 503A pharmacies, with a real provider at every visit
  • Boutique physician-led model bundling labs, peptides, HRT/TRT and urgent care; FSA/HSA eligible

Where it loses points

  • Florida-focused telehealth — availability outside FL is not advertised, so out-of-state access is uncertain
  • Medication cost is on top of a $199 initial consultation and $99 follow-up visits (pay-per-visit, not an all-in monthly price)
  • The 503A compounding pharmacy partner is not named on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard